{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:47:39Z","timestamp":1777952859994,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.gastrohep.2025.502647","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:12:08Z","timestamp":1766247128000},"page":"502647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Etrasimod: revisi\u00f3n de la seguridad y las consideraciones pr\u00e1cticas de manejo de una nueva terapia oral para el tratamiento de la colitis ulcerosa"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-8868","authenticated-orcid":false,"given":"Yamile","family":"Zabana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"C\u00e1bez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Guti\u00e9rrez Casbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2025.502647_bib0250","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0255","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s12325-023-02473-6","article-title":"Epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in Spain: A systematic review","volume":"40","author":"Barreiro-de Acosta","year":"2023","journal-title":"Adv Ther."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0260","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/jcm10132885","article-title":"Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: Large-scale epidemiological study","volume":"10","author":"Chaparro","year":"2021","journal-title":"J Clin Med."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0265","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0270","first-page":"95","article-title":"Clinical course and prognosis in ulcerative colitis: Results from population-based and observational studies","volume":"27","author":"Monstad","year":"2014","journal-title":"Ann Gastroenterol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0275","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/2050640620948795","article-title":"Long-term outcome of ulcerative proctitis","volume":"8","author":"Ungar","year":"2020","journal-title":"United European Gastroenterol J."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0280","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.MIB.0000225339.91484.fc","article-title":"Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (the IBSEN study)","volume":"12","author":"Henriksen","year":"2006","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0285","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3390\/cells12131730","article-title":"Novel small molecules in IBD: Current state and future perspectives","volume":"12","author":"Jefremow","year":"2023","journal-title":"Cells."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0290","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","article-title":"Modulation of sphingosine-1-phosphate in ulcerative colitis","volume":"20","author":"Argollo","year":"2020","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0295","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474124.2020.1785868","article-title":"PK, PD, and interactions: The new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD","volume":"14","author":"Gilardi","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0300","doi-asserted-by":"crossref","first-page":"502363","DOI":"10.1016\/j.gastrohep.2025.502363","article-title":"Etrasimod: revisi\u00f3n de la eficacia y las perspectivas terap\u00e9uticas de una nueva terapia oral para el tratamiento de la colitis ulcerosa","volume":"48","author":"Gisbert","year":"2025","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0305","unstructured":"Ficha t\u00e9cnica Velsipity\u00ae [consultado 20 Ago 2025]. Disponible en: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20240216161575\/anx_161575_es.pdf"},{"key":"10.1016\/j.gastrohep.2025.502647_bib0310","unstructured":"ClinicalTrials.gov. Safety and efficacy of etrasimod (APD334) in patients with ulcerative colitis [consultado 20 Ago 2025]. Disponible en: https:\/\/clinicaltrials.gov\/study\/NCT02447302"},{"key":"10.1016\/j.gastrohep.2025.502647_bib0315","unstructured":"ClinicalTrials.gov. Extension study of APD334-003 in patients with moderately to severely active ulcerative colitis. ID NCT02536404 [consultado 20 Ago 2025]. Disponible en: https:\/\/clinicaltrials.gov\/study\/NCT02536404"},{"key":"10.1016\/j.gastrohep.2025.502647_bib0320","unstructured":"ClinicalTrials.gov. Etrasimod versus placebo for the treatment of moderately to severely active ulcerative colitis [consultado 20 Ago 2025]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03945188"},{"key":"10.1016\/j.gastrohep.2025.502647_bib0325","unstructured":"ClinicalTrials.gov. Etrasimod versus placebo as induction therapy in moderately to severely active ulcerative colitis [consultado 20 Ago 2025]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03996369"},{"key":"10.1016\/j.gastrohep.2025.502647_bib0330","unstructured":"ClinicalTrials.gov. An extension study for treatment of moderately to severely active ulcerative colitis [consultado 20 Ago 2025]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03950232"},{"key":"10.1016\/j.gastrohep.2025.502647_bib0335","unstructured":"ClinicalTrials.gov. A phase 3 study of etrasimod in subjects with moderately to severely active ulcerative colitis [consultado 20 Ago 2025]. Disponible en: https:\/\/clinicaltrials.gov\/study\/NCT04176588"},{"key":"10.1016\/j.gastrohep.2025.502647_bib0340","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0345","article-title":"Sphingosine 1-phosphate: Lipid signaling in pathology and therapy","volume":"366","author":"Cartier","year":"2019","journal-title":"Science (1979)."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0350","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","article-title":"Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease","volume":"19","author":"Verstockt","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0355","article-title":"How do sphingosine-1-phosphate affect immune cells to resolve inflammation?","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0360","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/2211-5463.13907","article-title":"Unique pharmacological properties of etrasimod among S1P receptor modulators","volume":"15","author":"Gaidarov","year":"2025","journal-title":"FEBS Open Bio."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0365","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/imt-2022-0255","article-title":"Etrasimod for the treatment of ulcerative colitis","volume":"15","author":"Wils","year":"2023","journal-title":"Immunotherapy."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0370","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.3390\/biomedicines10071735","article-title":"Sphingosine 1-phosphate modulation in inflammatory bowel diseases: Keeping lymphocytes out of the intestine","volume":"10","author":"Dal Buono","year":"2022","journal-title":"Biomedicines."},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2025.502647_bib0375","doi-asserted-by":"crossref","first-page":"i701","DOI":"10.1093\/ecco-jcc\/jjac190.0705","article-title":"P575 Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"17","author":"Siegmund","year":"2023","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0380","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.14309\/01.ajg.0000860352.29232.aa","article-title":"S928 Effect of etrasimod on circulating lymphocytes in patients with moderately to severely active ulcerative colitis: Data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"117","author":"Danese","year":"2022","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0385","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjae060","article-title":"Etrasimod for the treatment of ulcerative colitis: Analysis of infection events from the ELEVATE UC clinical programme","volume":"18","author":"Regueiro","year":"2024","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0390","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1177\/10600280231225770","article-title":"Etrasimod: A sphingosine-1-phosphate receptor modulator for the treatment of ulcerative colitis","volume":"58","author":"Choi","year":"2024","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0395","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.14309\/01.ajg.0000776412.04273.9e","article-title":"S720 Pharmacokinetics (PK), safety, and tolerability of etrasimod (APD334) in participants with mild, moderate, or severe hepatic impairment: A single-dose, open-label, parallel-group study","volume":"116","author":"Lee","year":"2021","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2025.502647_bib0400","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1093\/ecco-jcc\/jjz203.525","article-title":"P396 Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects","volume":"14","author":"Lee","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2025.502647_bib0405","doi-asserted-by":"crossref","first-page":"i1320","DOI":"10.1093\/ecco-jcc\/jjad212.0835","article-title":"P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme","volume":"18","author":"Lichtenstein","year":"2024","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0410","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpdd.1379","article-title":"Safety, pharmacokinetics, and pharmacodynamics of etrasimod: Single and multiple ascending dose studies in healthy adults","volume":"13","author":"Lee","year":"2024","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2025.502647_bib0415","doi-asserted-by":"crossref","first-page":"i1055","DOI":"10.1093\/ecco-jcc\/jjad212.0670","article-title":"P540 Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials","volume":"18","author":"Lees","year":"2024","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0420","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0425","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: Results from the open-label extension of the OASIS study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0430","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet."},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2025.502647_bib0435","doi-asserted-by":"crossref","first-page":"i119","DOI":"10.1093\/ecco-jcc\/jjae190.0057","article-title":"DOP018 Etrasimod for the treatment of ulcerative colitis: Up to 4 years of safety data from the global clinical programme","volume":"19","author":"Vermeire","year":"2025","journal-title":"J Crohns Colitis."},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2025.502647_bib0440","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1093\/ecco-jcc\/jjx180.700","article-title":"P573 Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteers","volume":"12","author":"Peyrin-Biroulet","year":"2018","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0445","doi-asserted-by":"crossref","first-page":"S851","DOI":"10.1016\/S0016-5085(25)02898-7","article-title":"Su1837: Etrasimod for the treatment of ulcerative colitis: up to 4 years of safety data from the global clinical program. Presented at DDW 2025","volume":"169","author":"Vermeire","year":"2025","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0450","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/biom13050818","article-title":"Sphingosine-1-phosphate signaling in cardiovascular diseases","volume":"13","author":"Wang","year":"2023","journal-title":"Biomolecules."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0455","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpdd.1388","article-title":"Cardiovascular evaluation of etrasimod, a selective sphingosine 1-phosphate receptor modulator, in healthy adults: Results of a randomized, thorough QT\/QTc study","volume":"13","author":"Darpo","year":"2024","journal-title":"Clin Pharmacol Drug Dev."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0460","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2024-001516","article-title":"Cardiovascular events observed among patients in the etrasimod clinical programme: An integrated safety analysis of patients with moderately to severely active ulcerative colitis","volume":"12","author":"Vermeire","year":"2025","journal-title":"BMJ Open Gastroenterol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0465","doi-asserted-by":"crossref","first-page":"S675","DOI":"10.14309\/01.ajg.0000953260.59351.c7","article-title":"S905 Impact of etrasimod on blood pressure and hypertension: Data from the etrasimod ulcerative colitis clinical program","volume":"118","author":"Vermeire","year":"2023","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0470","doi-asserted-by":"crossref","first-page":"jjae173","DOI":"10.1093\/ecco-jcc\/jjae173","article-title":"Low incidence of macular edema and other ocular events in the etrasimod development program","volume":"19","author":"Dubinsky","year":"2025","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0475","first-page":"S816","article-title":"S1072 Hepatic impact of etrasimod for treatment of moderately to severely active ulcerative colitis: An integrated safety summary from the etrasimod ulcerative colitis clinical program","volume":"118","author":"Regueiro","year":"2023","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0480","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/1744666X.2019.1646127","article-title":"Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases","volume":"15","author":"Holmer","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0485","doi-asserted-by":"crossref","first-page":"S1032","DOI":"10.14309\/01.ajg.0001035116.14492.4e","article-title":"S1437 Pregnancy outcomes in the etrasimod clinical program","volume":"119","author":"Gecse","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2025.502647_bib0490","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11894-024-00923-x","article-title":"Managing risks with newer oral small molecules in patients with inflammatory bowel diseases","volume":"26","author":"Ayoub","year":"2024","journal-title":"Curr Gastroenterol Rep."}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525005175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525005175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:18:28Z","timestamp":1777900708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570525005175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0210570525005175"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502647","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etrasimod: revisi\u00f3n de la seguridad y las consideraciones pr\u00e1cticas de manejo de una nueva terapia oral para el tratamiento de la colitis ulcerosa","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502647"}}